Inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene predisposes to vascular tumor formation in several organs. VHL regulates two evolutionary conserved pathways: the targeting of hydroxylated hypoxia-inducible factor-a (HIF-a) for proteasomal degradation and the remodeling of extracellular matrix (ECM). The biochemical mechanisms of the ECM assembly pathway remain poorly defined. Here, we provide evidence supporting a biochemical role for VHL in ECM assembly. We show that VHL directly binds to the collagen IV alpha 2 (COL4A2) chain and that this interaction is necessary for its assembly into the ECM. The VHL-COL4A2 interaction is dependent on endoplasmic reticulum (ER)-mediated COL4A2 hydroxylation and independent of cytosolic, hypoxia regulated HIF-a-modifying enzymes. We find that the N-terminal tail of COL4A2 protrudes from the ER lumen into the cytosol where it is bound by VHL. Failure of VHL to interact with COL4A2 correlates with loss of collagen IV network formation in vitro and collagen IV remodeling in vivo. Our data suggest a HIF-a-independent role for the VHL-COL4A2 interaction in suppression of angiogenic tumor formation through collagen IV network assembly.
Introduction
von Hippel-Lindau (VHL) disease is a hereditary cancer syndrome caused by germline mutations in the VHL tumor suppressor gene Semenza, 2003; Barry and Krek, 2004) . The VHL syndrome is the most common syndrome of hereditary kidney cancer whereby affected individuals develop vascular tumors including clear cell renal cell carcinoma (RCC), together with hemangioblastomas of the central nervous system and retina, as well as pheochromocytomas Semenza, 2003; Barry and Krek, 2004) . Somatic mutations of the VHL gene have also been observed in sporadic forms of most VHL-associated tumors, including hemangioblastomas and clear cell RCC Semenza, 2003; Barry and Krek, 2004) . Two major conserved pathways have been described defining the role of VHL as a tumor suppressor: the hypoxia-inducible factor-a (HIF-a) pathway and the extracellular matrix (ECM) pathway. The HIF-a pathway involves the VHL protein as part of an E3 ubiquitin ligase complex that binds HIF-a leading to its polyubiquitination and proteasomal degradation. The VHL-HIF-a interaction is mediated by HIF-a hydroxylation at two proline residues by cytosolic prolyl hydroxylases (PHDs) that require oxygen, iron and the cofactor 2-oxoglutarate Semenza, 2003; Barry and Krek, 2004) . In cells that have lost the VHL ligase function, HIF-a accumulates leading to activation of HIF-a target genes including VEGF and transforming growth factor-a, thereby mimicking the cellular response to hypoxia. Genetic studies have identified an important role for the HIF-2a isoform in RCC tumorigenesis (Kondo et al., 2002; Zimmer et al., 2004; Raval et al., 2005) . Hypoxia-mimetics, including iron chelators, cobalt chloride (CoCl 2 ) and dimethyl-oxallylglycine (DMOG) inhibit PHD activity thus stabilizing HIF-a and resulting in induction of HIF-a target genes Semenza, 2003; Barry and Krek, 2004) .
Genotype/phenotype correlations suggested the existence of other HIF-a-independent, tumor suppressor mechanisms for VHL. This activity became apparent when VHL tumor-associated mutants, which maintain HIF-a binding/degradation, were reintroduced into VHL-negative 786-0 cells (Clifford et al., 2001; Hoffman et al., 2001 ). All VHL mutants tested so far failed to assemble an ECM in cell culture and could only be rescued by reintroduction of wild-type VHL (Ohh et al., 1998; Esteban-Barragan et al., 2002) . In Caenorhabditis elegans, VHL was shown to function along a HIF-adependent pathway and an ECM pathway independent of HIF-a suggesting evolutionary conservation of both pathways (Bishop et al., 2004) . The role of VHL in ECM assembly and tumor suppression correlated with VHL neddylation and its interaction with fibronectin. Therefore, the ECM assembly activity of VHL is considered essential for the VHL tumor suppressor function (Ohh et al., 1998; Stickle et al., 2004; Kurban et al., 2006) . Recently, we have shown that inactivation of the VHL-ECM assembly pathway results in highly vascular tumors with remodeled ECM and increased matrix metalloprotease-2 (MMP-2) activity. Loss of the VHL-HIF-a degradation pathway resulted in tumors with increased VEGF levels but surprisingly low microvessel density, a tightly assembled ECM and low invasive ability (Kurban et al., 2006) . These studies confirmed that both VHL pathways are important for suppression of tumorigenesis and angiogenesis.
In the present study, we identify collagen IV alpha 2 (COL4A2) as a VHL binding partner. We find the interaction to be specific for the COL4A2 chain and mediated by hydroxylation of COL4A2 residues. We also show that the VHL-COL4A2 interaction occurs at the endoplasmic reticulum (ER) resulting in COL4A2 network formation. Loss of this interaction in tumor-causing VHL mutants results in disruption of collagen IV network formation in vitro and remodeling of collagen IV matrix in vascularized VHL tumors. Our results point to the importance of the VHL-COL4A2 interaction in regulating ECM assembly and provide insight into the role of this interaction in suppression of angiogenic tumor formation.
Results

Identification of COL4A2 as a VHL interacting protein
We previously demonstrated that VHL co-immunoprecipitates and interacts directly with a 200 kDa protein (Iwai et al., 1999) . In our current study, we used the VHL-negative RCC cell line 786-0, either stably expressing wild-type HA-VHL (WT8, WT7 and WTE), or wild-type HA-VHL along with a non-degradable form of HIF-a (PA) or mutant forms of HA-VHL (L188V and R64P) that are functional in the HIF-a interaction/ degradation pathway but defective in the ECM assembly pathway (Hoffman et al., 2001; Kondo et al., 2002; Kurban et al., 2006) . We performed 35 S metabolic labeling followed by HA immunoprecipitation (IP) using total cell extracts ( Figure 1a ). An interaction between VHL and p200 was observed in cells expressing wild-type VHL (WT8, WT7, WTE and PA) but not tumor-associated VHL mutants (L188V and R64P). 786-0 and pRC cell lines, which lack VHL, were used as control and showed no interaction with p200 ( Figure 1a ). P200 was identified by mass spectrometry that revealed five peptides whose sequences matched that of COL4A2 (Figure 1b) . To confirm the mass spectrometry results, VHL was immunoprecipitated from total extracts of the various 786-0 cell lines and analysed by western blot using anti-COL4A2 (H22) (Figure 1c VHL-COL4A2 interaction and ECM assembly G Kurban et al the same interaction between COL4A2 and VHL in HeLa cells expressing Flag-tagged VHL (data not shown). Taken together, these results suggest that COL4A2 is a specific VHL binding partner.
VHL co-immunoprecipitates and interacts directly with COL4A2
To further characterize the COL4A2-VHL interaction, collagen IV was immunoprecipitated from total cell lysates of the various 786-0 cell lines using a polyclonal anti-collagen IV antibody. Western blot analysis revealed that only wild-type VHL (WT7) and not the VHL mutant protein (R64P) co-immunoprecipitated with collagen IV (Figure 2a ). To determine if the VHL-COL4A2 is a direct interaction, far-western analysis was performed on VHL immunoprecipitates from pRC, WT7 and R64P cell lysates using radioactively labeled active VHL complex consisting of elongins B and C (VBC- Figure 2b with anti-fibronectin antibody revealed a higher migrating band whose size did not match the COL4A2 band ( Figure 2d ). pRC cells were used as control for the different experiments and showed no VHL or collagen binding. These results suggest that VHL directly interacts with COL4A2 whereas the VHL-fibronectin interaction appears to be indirect.
VHL specifically binds to COL4A2
To determine the specificity of VHL for COL4A2, 786-0 cells expressing wild-type VHL (WT7) were transfected with COL4A2 siRNA. Western blot analysis showed COL4A2 downregulation ( Figure 3a , upper panel), which was not observed in control scrambled siRNA or lipofectamine-only transfected cells. Far-western experiments showed that the intensity of the band interacting with VBC-32 P decreased significantly upon COL4A2 siRNA transfection, suggesting that VHL binds specifically to COL4A2 ( Figure 3a , middle panel). Figure 3b shows that collagen IV alpha 1 (COL4A1) levels did not decrease upon COL4A2 siRNA transfection but appeared to slightly increase probably due to a compensatory mechanism and there was no significant decrease in fibronectin levels confirming specificity of the COL4A2 siRNA. To further test, the specificity of VHL to COL4A2, the following experiments were performed. VHL was immunoprecipitated from WT7 and R64P cell extracts and western blot analysis for collagen 18 (COL18) revealed that there was no interaction between VHL and COL18 ( Figure 3c , upper panel). WT7 total extracts were used as positive control and showed expression of COL18 ( Figure 3c , upper panel, lane 4). On the other hand, VHL IP from WT7 cell extracts showed that both COL4A2 and COL4A1 co-immunoprecipitated with VHL and this was not observed in R64P cells or pRC control cells ( Figure 3d ). However, far-western analysis of total cell lysates from WT7 or pRC cells revealed that the size of the band interacting with VBC-32 P complex corresponded to COL4A2 and not COL4A1 (Figure 3e ) suggesting that the interaction of VHL with COL4A1 is an indirect one whereas the VHL-COL4A2 interaction is direct. Taken together, these results confirmed the specific direct binding of VHL to COL4A2.
The interaction of VHL with COL4A2 is dependent on hydroxylation by ER and not cytosolic hydroxylases Since VHL forms a conserved binding pocket for hydroxylated prolines, it is possible that hydroxylated proteins other than HIF-a would associate with it (Min et al., 2002) . To determine whether the VHL-COL4A2 interaction is mediated by hydroxylation similar to the VHL-HIF-a interaction, WT7 cells were treated with desferrioxamine (DFO), an iron chelator that inhibits both cytosolic and ER hydroxylases. As a control for the DFO treatment, HIF-2a levels were checked, and, as Collagens were shown to undergo prolyl and lysyl hydroxylation events followed by glycosylation of these residues before secretion (Prockop and Kivirikko, 1995 VHL-COL4A2 interaction and ECM assembly G Kurban et al hydroxylation of prolines and lysines and associated glycosylation of COL4A2 residues, since a lower migrating COL4A2 was observed by western blot analysis (Figure 4a, upper panel, lane 3) . To determine whether the VHL-COL4A2 interaction was dependent on cytosolic HIF-a prolyl hydroxylases, WT7 cells were treated with CoCl 2 , a hypoxia mimetic that only inhibits the cytosolic oxygen-sensitive prolyl hydroxylases. The VHL-COL4A2 interaction was not affected by CoCl 2 treatment suggesting that ER localized collagen IVmodifying and not cytosolic hydroxylases were involved (Figure 4b In line with the role of VHL in ubiquitination and degradation, we tested if VHL was involved in proteasomal degradation of COL4A2. Upon treatment of WT7 cells with the proteasome inhibitor MG132, COL4A2 levels did not increase (Figure 4a , upper panel, lane 2) and the VHL-COL4A2 interaction was not affected (Figure 4b , upper panel, lane 2; middle panel, lane 2) suggesting that VHL is not involved in COL4A2 degradation. HIF-2a levels were tested as control for the MG132 treatment and showed an increase as determined by western blot analysis (Figure 4a , middle panel, lane 2). Taken together, these data suggest that the VHL-COL4A2 interaction is mediated by ER hydroxylation on COL4A2 residues and is not related to the known E3 ligase function of VHL involved in protein degradation.
The VHL-COL4A2 interaction occurs at the ER VHL is predominantly a cytosolic protein that shuttles to the nucleus and was also shown to be present at the ER (Schoenfeld et al., 2001) . Collagen IV, however, is a secreted protein, which is modified in the ER, leading to triple helix formation, an event involving interaction of two COL4A1 chains with one COL4A2 chain (Prockop and Kivirikko, 1995) . The triple helix is transported along the secretory pathway, and assembled extracellularly into a network. However, most of the assembly events are poorly defined at the molecular level. To determine how VHL, a cytosolic protein, and COL4A2, an ECM component might interact, we determined the localization of VHL and COL4A2 in WT7 cells using indirect immunofluorescence. Figure 5a shows that VHL (red) and COL4A2 (green) colocalize at the ER region (yellow). To confirm the interaction site, biochemical fractionation of cells was performed to isolate cytosolic and ER fractions followed by western blot analysis. VHL was found to be present in the cytosolic and ER fractions (Figure 5b, panel 2) . Upon trypsinization of the ER fraction to remove proteins bound to the ER membrane, VHL was no longer detectable suggesting that VHL was attached to the outside of the ER membrane and was not present in the lumen (Figure 5b , panel 2). COL4A2 localization was determined by western blot analysis using a specific anti-COL4A2 antibody (H22) that recognizes the C-terminal NC1 fragment of COL4A2, and showed that COL4A2 was present predominantly in the ER fraction. Trypsinization of the ER fraction resulted in a lumenally protected E130 kDa band corresponding to the C-terminal portion of COL4A2 (Figure 5b, panel 1) . This suggested that the N-terminal portion of COL4A2 was protruding from the ER and exposed to the cytosol, which led to its digestion by trypsin, whereas the C-terminal region of COL4A2 was protected in the ER lumen. Western blot analysis for actin showed that the ER fractions were not contaminated with cytosolic proteins (Figure 5b, panel  3) . To control for trypsinization, we used an ER marker, calnexin, which is a protein spanning the ER membrane. Using an anti-calnexin antibody that recognizes the cytosolic part of the protein, full-length calnexin was observed in the ER fractions and, upon trypsinization, was no longer detected ( Figure 5b, panel 4) , confirming efficient trypsinization of the ER membrane. To 
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G Kurban et al determine whether the ER lumen was intact, an antibody recognizing the lumenal portion of calnexin was used and revealed full-length calnexin protein in the ER fraction (Figure 5b , panel 5). However, upon ER trysinization, the full-length protein disappeared and a smaller fragment corresponding to the protected lumenal part was observed (Figure 5b , panel 5) confirming that integrity of the ER lumen and membrane was maintained upon trypsinization. Far-western analysis using VBC-32 P showed that VHL interacted with fulllength COL4A2 but not with the E130 kDa C-terminal fragment (Figure 5c ), thus limiting the VHL-COL4A2 interaction site to the E70 kDa N-terminal portion of COL4A2. These data suggest that the VHL-COL4A2 interaction occurs at the ER membrane where VHL binds to the N terminal of COL4A2 protruding into the cytosol.
The VHL-COL4A2 interaction results in collagen IV network assembly thus maintaining integrity of the basement membrane Remodeling of ECM is associated with formation of highly vascularized tumors (Handsley and Edwards, 2005; Kurban et al., 2006) . Collagen IV is the major component of basement membranes predominantly composed of two a1 chains and one a2 chain arranged into a triple helix. Therefore, we tested whether the VHL-COL4A2 interaction had an effect on COL4A2 and COL4A1 matrix assembly using antibodies that recognize triple helical structure of both proteins. Figure 6a shows that cells lacking VHL (pRC) and cells expressing VHL mutant R64P were unable to assemble a COL4A2 matrix but upon reintroduction of wild-type VHL (WT7 and WT8), assembly of COL4A2 extracellular network was observed. To test the ability of VHL-COL4A2 interaction and ECM assembly G Kurban et al VHL to form collagen IV matrix in vivo, PA, SKRC, pRC and R64P cells were injected sub-cutaneously in nude mice and were found to produce tumors (Kurban et al., 2006) . Tumors produced by kidney cancer cells expressing VHL (PA and SKRC) showed a tight and densely assembled COL4A1 matrix (Figure 6b ). This was not observed in pRC and R64P cells where COL4A1 matrix was remodeled and loose ( Figure 6b ) positively correlating with the increased blood vessel infiltration previously detected in these tumors (Kurban et al., 2006) . These results highlight the importance of the VHL-COL4A2 interaction in collagen IV matrix assembly.
Discussion
In this study, we present a novel HIF-a-independent interaction between VHL and COL4A2 that is necessary for COL4A2 matrix assembly. The COL4A2 chain forms a triple helix with COL4A1, which in turn associates with fibronectin, importantly indicating that the previously described VHL-fibronectin interaction is indirect (Supplementary Materials). The VHL-COL4A2 interaction is disrupted by tumor-associated VHL mutations suggesting that it is an important component of the VHL tumor suppressor function. The binding of VHL to COL4A2 positively correlates with the ability of cells to assemble a proper extracellular collagen IV matrix in vitro and in vivo. Therefore, loss of VHL function results in a disruption of VHL binding to collagen IV and fibronectin, leading to remodeled ECM amenable to blood vessel infiltration. We and others have recently shown that lack of ECM assembly results in tumor formation, angiogenesis and invasion in RCC (Stickle et al., 2004; Kurban et al., 2006) . However, the precise molecular mechanism of the VHL-COL4A2 interaction in ECM assembly is still unclear.
The VHL protein forms an E3 ubiquitin ligase complex and binds to prolyl hydroxylated HIF-a leading to its ubiquitination and degradation. We have shown here that the VHL-elongins B and C complex interacts directly with COL4A2, but could not detect ubiquitination and degradation of COL4A2 upon treatment with proteasome inhibitors. This suggests an alternative mechanism of action for VHL in the regulation of collagen IV matrix assembly that is independent of its ligase activity. Exploring the role of VHL in the regulation of collagen IV assembly will shed light on a novel function of this tumor suppressor.
Inhibition of proline and lysine hydroxylation by an iron chelator led to abrogation of collagen and HIF-a binding suggesting that the interaction of VHL with both proteins is dependent on hydroxylated amino acids and may involve a similar overlapping binding region in VHL. In case of HIF-a, two prolines are modified by cytosolic PHDs that are regulated by oxygen tension. Collagen contains a vast number of lysines and prolines known to be hydroxylated. Hydroxylation is followed by glycosylation leading to proper triple helix formation and secretion. However, collagen modifications are carried out in the ER lumen by prolyl and lysyl hydroxylases, which are independent of oxygen tension (Prockop and Kivirikko, 1995) . Indeed, when cells were treated with the hypoxia mimetic CoCl 2 , the VHL-collagen interaction remained unaffected whereas the VHL-HIF-a interaction was disrupted as shown previously (Epstein et al., 2001; Semenza, 2003; Barry and Krek, 2004) . These results suggest that VHL-COL4A2 interaction and ECM assembly G Kurban et al the modifications are carried out by different enzymes in different compartments suggesting an independent regulation of the two VHL pathways.
In the mass spectrometric analysis, we only found COL4A2 peptides, but not peptides from COL4A1 or other collagen chains. All collagens contain a collagenous domain in the center of their sequence consisting of repeated hydroxylated lysines and prolines. Therefore, if VHL recognizes any hydroxylated residue, it should interact with all collagens. There is currently no evidence in the literature suggesting that collagens are cytosolic proteins or that VHL is part of the secretory pathway. We show here that VHL interacts with the N-terminal part of COL4A2 at the cytosolic side of the ER suggesting that the N-terminus of COL4A2 reaches into the cytosol where it is bound by VHL after ER hydroxylation of one or more collagen residues. Since triple helix formation of collagens is initiated by the C-terminal NC1 domain, it is likely that both COL4A2 and COL4A1 chains form a partial triple helix in the ER starting from the C-terminal NC1 domain (Soder and Poschl, 2004) . The complete formation of a mature triple helix might be regulated by the binding of VHL to the N-terminal cytosolic portion of COL4A2. It is not clear whether this VHL-dependent process affects triple helix formation and/or secretion but our results show that the VHL-COL4A2 interaction is crucial for extracellular COL4A2 network formation.
While we were preparing this manuscript, a study showing interaction of VHL with collagen IV was published (Grosfeld et al., 2007) . We further confirm these results in our present study and move on to show the specificity of VHL to COL4A2, the ER localization of the VHL-COL4A2 interaction as well as the dependence of ECM assembly on this interaction. Our present data show the first direct molecular connection between a tumor suppressor protein and assembly of the collagen IV matrix. The next major challenge will be to elucidate the exact molecular mechanism of the VHL-collagen interaction leading to ECM assembly. This will have important implications in the molecular connections between ECM assembly/remodeling and tumor formation/angiogenesis.
Materials and methods
Cells and cell culture 786-0 RCC cell lines and stable transfectants of 786-0 have been described previously (Kurban et al., 2006) . VHL positive SKRC kidney cancer cells were kindly provided by Dr Laura Schmidt (NIH).
Transfections
Cells were transfected with lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) and either scrambled siRNA with target sequence AACGCCUAUAAGCUCAGACUG, fibronectin siRNA with target sequence AAGCAGCACAACUUCGA AUUA or COL4A2 siRNA with target sequence AACUUAU GCACUGCCUAAAGA.
Immunofluorescence
For colocalization experiments, cells on coverslips were incubated with anti-COL4A2 (H22) and anti-VHL antibodies followed by incubation with rhodamine-conjugated antimouse and Alexa Fluor 488 anti-rat antibodies.
For in vitro matrix assembly, cells on coverslips were incubated with anti-COL4A2 (MAB 1910) followed by incubation with FITC anti-mouse antibody. Visualization was performed using Zeiss LSM 5 Pascal on Axiovert 200 confocal microscope.
Isolation of cytosolic and ER fractions
Cells were homogenized in HIM buffer (200 mM mannitol, 70 mM sucrose, 10 mM HEPES, 1 mM EGTA pH to 7.5) using a Teflon homogenizer. The homogenates were spun at 9000 r.p.m. and the resulting supernatants were then spun at 100 000 g separating the cytosolic extracts from the ER fractions. ER fractions were resuspended in HIM buffer. A measure of 30 mg of protein was treated with 3 mg of trypsin on ice for 15 min. Trypsin was inactivated with protease inhibitors (Roche, Laval, Quebec, Canada) followed by addition of 2 Â Laemmli buffer containing dithiothreitol and boiling.
